IRVINE, Calif., Dec. 16, 2015 (GLOBE NEWSWIRE) -- CombiMatrix Corporation (NASDAQ: CBMX ), a molecular diagnostics company specializing in DNA-based testing services for prenatal, miscarriage analysis, postnatal developmental disorders, and pre-implantation genetic screening (PGS) services, today announced that it has launched its PGS Multicycle Program. The PGS Multicycle Program provides patients the flexibility of testing eight embryos over the course of 12 months for a one-time payment. CombiMatrix is the pioneer in per-embryo pricing in conjunction with PGS testing. With the addition of a multicycle PGS option, CombiMatrix continues to offer the most flexible, cost-effective solutions for patients while increasing the upfront cash payments received for genetic testing services.
“By offering the PGS Multicycle Program, we are making PGS more cost effective for physicians and their patients. We are delighted to provide an additional option to our existing flexible ‘per embryo’ pricing structure, where patients pay only for those embryos being tested,” said Mark McDonough, President and Chief Executive Officer of CombiMatrix. “In leveraging our commercial expertise and offering disruptive solutions such as the only nationwide PGS testing program with built-in shipping cost for transparency, we are further strengthening our position in this growing market.”
“Additionally, we have implemented PGS shipping process improvements, resulting in increased convenience to physicians and embryologists, as well as providing significant cost reductions. This gives us operating leverage and allows us to pass further savings onto IVF clinics and their patients,” McDonough added.
CombiMatrix employs innovative ways to provide unique, value-added options to its offerings, such as:
- No separate charge for embryo batching
- Pre-labeled barcode scanning for extra embryo security and tracking
- Biopsy services utilizing CombiMatrix embryologist and equipment (laser provided)
- Free access to the company’s embryologist for PGS customers
- Easy-to-use online provider portal to view status reports
“Our continued focus on our customers and their patients is evident in the high-tech, high-touch approach to our service offerings,” concluded McDonough.
About CombiMatrix Corporation
CombiMatrix Corporation provides valuable molecular diagnostic solutions and comprehensive clinical support to foster the highest quality in patient care. CombiMatrix specializes in pre-implantation genetic screening, miscarriage analysis, prenatal and pediatric diagnostics, offering DNA-based testing for the detection of genetic abnormalities beyond what can be identified through traditional methodologies. CombiMatrix performs genetic testing utilizing a variety of advanced cytogenomic techniques, including chromosomal microarray, standardized and customized fluorescence in situ hybridization (FISH) and high-resolution karyotyping. CombiMatrix is dedicated to providing high-level clinical support for healthcare professionals in order to help them incorporate the results of complex genetic testing into patient-centered medical decision making. Additional information about CombiMatrix is available at www.combimatrix.com or by calling (800) 710-0624.
Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995
This press release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. These statements are based upon our current expectations, speak only as of the date hereof and are subject to change. All statements, other than statements of historical fact included in this press release, are forward-looking statements. Forward-looking statements can often be identified by words such as "anticipates," "expects," "intends," "plans," "goal," "predicts," "believes," "seeks," "estimates," "may," "will," "should," "would," "could," "potential," “optimistic,” "continue," "ongoing," similar expressions, and variations or negatives of these words and include, but are not limited to, statements regarding projected results of operations and management's future business, operational and strategic plans, recruiting efforts and test menu expansion. These forward-looking statements are not guarantees of future results and are subject to risks, uncertainties and assumptions that could cause our actual results to differ materially and adversely from those expressed in any forward-looking statement. The risks and uncertainties referred to above include, but are not limited to: our ability to successfully market our PGS Multicycle Program and other diagnostic test offerings, to successfully expand the base of our customers and strategic partners, add to the menu of our diagnostic tests, develop and introduce new tests and related reports, expand and improve our current suite of services, optimize the reimbursements received for our microarray testing services, and increase operating margins by improving overall productivity and expanding sales volumes; our ability to successfully accelerate sales, steadily increase the size of our customer rosters in both prenatal and developmental genetic testing markets; our ability to attract and retain a qualified sales force in wider geographies; our ability to ramp production from our sales force and our strategic partners; rapid technological change in our markets; changes in demand for our future services; legislative, regulatory and competitive developments; general economic conditions; and various other factors. Further information on potential factors that could affect our financial results is included in our Annual Report on Form 10-K, Quarterly Reports of Form 10-Q, and in other filings with the Securities and Exchange Commission. We undertake no obligation to revise or update publicly any forward-looking statements for any reason, except as required by law.
Company Contact: Mark McDonough President & CEO, CombiMatrix Corporation (949) 753-0624 Investor Relations Contact: LHA Jody Cain (310) 691-7100 jcain@lhai.com
